干扰素联合微卡治疗慢性乙型肝炎  

Interferon combined with M.Vaccae in the treatment of chronic hepatitis B.

作　　者：文彬[1] 杨桂林[1] 胡毅文[1] 

机构地区：[1]深圳市东湖医院,广东深圳518020

出　　处：《现代医药卫生》2003年第6期670-671,共2页Journal of Modern Medicine & Health

摘　　要：目的:探讨干扰素联合微卡治疗慢性乙型肝炎的作用机制及疗效。方法:接诊断标准选择慢性乙型肝炎患者80例,随机分为干扰素联合微卡为治疗组(40例)和干扰素为对照组(40例),观察比较两组患者肝功能、HBeAg及HBVDNA的变化。结果:治疗组的肝功复常率、HBeAg及HBVDNA阴转率均明显高于对照组(P<0.05)。结论:干扰素联合微卡治疗慢性乙型肝炎有协同作用,它能提高细胞免疫应答能力,促进HBeAg及HBVDNA的阴转,减少病毒的变异,延迟耐药性的发生。Objective: To study the effects of interferon combined with M. Vaccae in the treatment of chronic hepatitis B . Methods: 80 cases with chronic hepatitis B were chosen according to diagnostic Standard of chronic hepatitis B. These cases were divided into two groups randomly, treatment group of 40 cases received interferon combined with M. Vaccae and control group of 40 cases received interferon. We observed the changes of transaminase ,HBeAg and HBV DNA. Results:The recovery rate of transaminase of treatment group was higher than that of control group, The negative rate of HBeAg and HBV DNA was also higher than that of control group, and differences were significant between two groups (P<0.05). Conclusion:There is a cooperative effect with interferon combined with M. Vaccae to treat chronic hepatitis B . it can improve cellular immune func-tion, make HBeAg and HBV DNA change negative ,decrease mutation of virus genotype ,delay resistance of drugs.

关 键 词：慢性乙型肝炎 干扰素 微卡 治疗 作用机制 疗效 

分 类 号：R512.62[医药卫生—内科学] R978.7[医药卫生—临床医学]